GEORGIA DORIS TOMARAS

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Improving peptide-MHC class I binding prediction for unbalanced datasets
    Ana Paula Sales
    Center for Computational Immunology, Duke University, Durham, NC 27705, USA
    BMC Bioinformatics 9:385. 2008
  2. ncbi CD8+ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I
    G D Tomaras
    Department of Surgery, Center for AIDS Research, Duke University Medical Center, Durham, NC 27710, USA
    Front Biosci 6:D575-98. 2001
  3. ncbi Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
    Georgia D Tomaras
    Duke Human Vaccine Institute, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 82:12449-63. 2008
  4. ncbi HIV-1-specific antibody responses during acute and chronic HIV-1 infection
    Georgia D Tomaras
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin HIV AIDS 4:373-9. 2009
  5. ncbi Strategies for eliciting HIV-1 inhibitory antibodies
    Georgia D Tomaras
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin HIV AIDS 5:421-7. 2010
  6. ncbi Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals
    Georgia D Tomaras
    Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Box 2926, Durham, NC 27710, USA
    J Virol 85:11502-19. 2011
  7. ncbi In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth
    Xiaoying Shen
    Duke Human Vaccine Institute, Duke University Medicine Center, Durham, NC 27710, USA
    J Virol 83:3617-25. 2009
  8. ncbi Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution
    Xiaoying Shen
    Department of Surgery, Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:5972-7. 2010
  9. ncbi Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
    Feng Gao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Virology 394:91-8. 2009
  10. ncbi HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 183:2708-17. 2009

Research Grants

  1. HIV-1 Gene Suppression by CD8+T Cell
    Georgia Tomaras; Fiscal Year: 2005
  2. HIV-1 Gene Suppression by CD8+ T Cells
    GEORGIA DORIS TOMARAS; Fiscal Year: 2010

Detail Information

Publications29

  1. ncbi Improving peptide-MHC class I binding prediction for unbalanced datasets
    Ana Paula Sales
    Center for Computational Immunology, Duke University, Durham, NC 27705, USA
    BMC Bioinformatics 9:385. 2008
    ..Although there is no consensus on the ideal class distribution for training sets, extremely unbalanced datasets can be detrimental to the performance of prediction algorithms...
  2. ncbi CD8+ T cell mediated noncytolytic inhibition of human immunodeficiency virus type I
    G D Tomaras
    Department of Surgery, Center for AIDS Research, Duke University Medical Center, Durham, NC 27710, USA
    Front Biosci 6:D575-98. 2001
    ..This review focuses on this antiviral activity by CD8+ T lymphocytes, which is distinct from that activity elicited by some cytolytic CD8+ T lymphocytes (CTLs)...
  3. ncbi Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
    Georgia D Tomaras
    Duke Human Vaccine Institute, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 82:12449-63. 2008
    ..These results demonstrate that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection...
  4. ncbi HIV-1-specific antibody responses during acute and chronic HIV-1 infection
    Georgia D Tomaras
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin HIV AIDS 4:373-9. 2009
    ....
  5. ncbi Strategies for eliciting HIV-1 inhibitory antibodies
    Georgia D Tomaras
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin HIV AIDS 5:421-7. 2010
    ..We review examples of strategies for eliciting potentially protective HIV-1 inhibitory antibodies...
  6. ncbi Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals
    Georgia D Tomaras
    Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Box 2926, Durham, NC 27710, USA
    J Virol 85:11502-19. 2011
    ..The broadly reactive HIV-1 neutralization observed in some subjects is mediated by antibodies targeting several conserved regions on the HIV-1 envelope glycoprotein...
  7. ncbi In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth
    Xiaoying Shen
    Duke Human Vaccine Institute, Duke University Medicine Center, Durham, NC 27710, USA
    J Virol 83:3617-25. 2009
    ..Our findings suggest that multiple events (i.e., genetic predisposition and HIV-1 immune dysregulation) may be required for induction of broadly reactive gp41 MPER antibodies in natural infection...
  8. ncbi Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution
    Xiaoying Shen
    Department of Surgery, Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:5972-7. 2010
    ..These data suggest that a major contribution to the L669S mutant virus phenotype of enhanced susceptibility to MPER mAbs is prolonged exposure of the MPER neutralizing epitope during viral entry...
  9. ncbi Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
    Feng Gao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Virology 394:91-8. 2009
    ..Nonetheless, such mAbs represent valuable reagents to study the biochemistry and structural biology of Env protein oligomers...
  10. ncbi HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 183:2708-17. 2009
    ..The inability to generate high titers of long-lived anti-envelope Abs is a major hurdle to overcome for the development of a successful HIV-1 vaccine...
  11. ncbi Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection
    Marc C Levesque
    Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS Med 6:e1000107. 2009
    ..While the effect of HIV-1 on depletion of gut CD4(+) T cells in acute HIV-1 infection is well described, we studied blood and tissue B cells soon after infection to determine the effect of early HIV-1 on these cells...
  12. ncbi Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage
    Kevin O Saunders
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Cell Immunol 266:154-64. 2011
    ..We define a multifactorial cytokine profile of CD8(+) T-lymphocytes capable of mediating noncytolytic suppression of CXCR4-tropic HIV-1 replication...
  13. ncbi B cell responses to HIV-1 infection and vaccination: pathways to preventing infection
    Barton F Haynes
    Duke Human Vaccine Institute and the Duke Center for AIDS Research, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
    Trends Mol Med 17:108-16. 2011
    ....
  14. ncbi Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines
    M Anthony Moody
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Exp Med 207:763-76. 2010
    ..The release of these beta-chemokines explains both the specificity for R5 HIV-1 and the activity of these mAbs in PBMC cultures containing both primary lymphocytes and monocytes...
  15. ncbi Is developing an HIV-1 vaccine possible?
    Barton F Haynes
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    Curr Opin HIV AIDS 5:362-7. 2010
    ..This review discusses select recent data that suggest that indeed it is possible to make a clinically useful preventive vaccine for HIV-1 and outlines some of the remaining obstacles that stand in the way of success...
  16. ncbi Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection
    S Munir Alam
    Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
    J Virol 82:115-25. 2008
    ....
  17. ncbi Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance
    Susan S Kaplan
    Department of Medicine, Duke University Medical Center, Durham, NC 22710, USA
    AIDS Res Hum Retroviruses 21:13-6. 2005
    ..Thus, CD4(+)/VL discordance can be maintained for periods exceeding 5 years in some patients receiving PI-based HAART without significant evolution of HIV resistance...
  18. ncbi Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination
    Stephanie A Freel
    Duke University Human Vaccine Institute, Departments of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 84:4998-5006. 2010
    ..Our data define attributes of an antiviral CD8(+) T-cell response that may be optimized in the search for an efficacious HIV-1 vaccine...
  19. ncbi Epigenetic regulation of CD8(+) T-lymphocyte mediated suppression of HIV-1 replication
    Kevin O Saunders
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, USA
    Virology 405:234-42. 2010
    ..These data provide a way to focus the search for the suppressive factors and to potentially modulate their expression...
  20. ncbi Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 85:11196-207. 2011
    ....
  21. ncbi Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control
    Susan A Sufka
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Infect Dis 187:1027-37. 2003
    ..These findings suggest that discordant responses may be related to enhanced HIV-directed immune responses, diminished cellular activation, decreased viral replication capacity, and preservation of non-syncytium-inducing virus strains...
  22. ncbi Tat-SF1 is not required for Tat transactivation but does regulate the relative levels of unspliced and spliced HIV-1 RNAs
    Heather B Miller
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 4:e5710. 2009
    ..At the onset of this work, the prevailing hypothesis was that Tat-SF1 was a required cofactor for the viral regulatory protein, Tat; however, this had not previously been formally tested in vivo...
  23. ncbi Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 44:203-12. 2007
    ..We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy...
  24. ncbi Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
    Paul A Goepfert
    University of Alabama at Birmingham, 908 20th Street South, CCB 328, Birmingham, AL 35294, USA
    Vaccine 25:510-8. 2007
    ..Use of the recombinant proteins NefTat and gp120(W61D) formulated with the AS02A adjuvant system was previously shown to protect against AIDS in a rhesus macaque SHIV animal model system...
  25. ncbi Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120
    Farley Cleghorn
    Center for HIV AIDS, Constella Futures, Washington, DC, USA
    J Acquir Immune Defic Syndr 46:222-30. 2007
    ..vCP1452 was administered alone or with a heterologous boost of MN rgp120 glycoprotein. The trial was pivotal in deciding whether these vaccines advanced to phase 3 efficacy trials...
  26. ncbi Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women
    Daniel C Johnson
    Sinai Children s Hospital and Rosalind Franklin University of Medicine and Science, North Chicago, IL 60608, USA
    J Infect Dis 192:2129-33. 2005
    ..33) TCID(50) vaccine formulation). Rare mucosal immunoglobulin A responses and no measurable vaccine-elicited serum antibodies were detected. In children, vCP205 appeared to be safe and immunogenic...
  27. ncbi Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    ....
  28. ncbi HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers
    Elizabeth J McFarland
    Department of Pediatric Infectious Diseases, University of Colorado Health Sciences Center, Denver Colorado, USA
    AIDS 20:1481-9. 2006
    ..This study evaluated the safety and immunogenicity of ALVAC HIV-1 vaccine with and without a subunit envelope boost in infants born to HIV-1-infected women...
  29. ncbi High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects
    Paul A Goepfert
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    J Infect Dis 192:1249-59. 2005
    ..0) TCID50 (60 participants) than when given at the regular dose, 10(7.26) TCID50 (40 participants); as a control, a placebo vaccine preparation also was administered (10 participants)...

Research Grants6

  1. HIV-1 Gene Suppression by CD8+T Cell
    Georgia Tomaras; Fiscal Year: 2005
    ..These studies will further our understanding of this potent means of virologic control and promote the development of this host cellular immune response in future therapeutic and vaccination strategies. ..
  2. HIV-1 Gene Suppression by CD8+ T Cells
    GEORGIA DORIS TOMARAS; Fiscal Year: 2010
    ..The results from this study will determine if induction of noncytolytic CD8 T cells would be beneficial in a protective vaccination strategy or whether it should be restricted to disease-modifying vaccine strategies. ..